Company: Stanford University School of Medicine
Job title: Professor
Dr. C. Garrison Fathman is Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University School of Medicine and Associate Director of the Institute for Immunology, Transplantation and Infection (ITI) and Director of the Center for Clinical Immunology at Stanford (CCIS). He was Founder and first-President of the Federation of Clinical Immunology Societies (FOCIS). His substantial scientific contributions in the areas of cellular and molecular immunology have brought him international recognition. As Director of the CCIS, Dr. Fathman has initiated a multidisciplinary approach to study and treat autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and insulin-dependent diabetes mellitus, and has initiated several new approaches to education and community outreach.
Dr. Fathman received his M.D. from Washington University in St. Louis in 1969. He subsequently completed his residency training at Dartmouth Affiliated Hospitals and completed a fellowship in immunology and rheumatology at Stanford University. Dr. Fathman then spent four years doing research, first as a clinical associate at the National Cancer Institute of the NIH, and then as a member of the Basel Institute of Immunology in Switzerland. He returned to the United States to join the faculty at the Mayo Clinic Medical School in 1977 and was recruited back to Stanford University in 1981.
Dr. Fathman is a member of many professional organizations, including the American Association of Immunologists (AAI) and the Association of American Physicians (AAP), and is past council member of the American Society for Clinical Investigation (ASCI) and past-President of the Clinical Immunology Society (CIS). He was Associate Editor of the Annual Review of Immunology for 25 years and serves on the editorial boards of numerous scientific journals. Dr. Fathman has chaired a variety of national and international professional meetings, served on NIH study sections and numerous blue-ribbon panels and has published more than 350 articles on his research. His recent work on understanding and correcting a defect in IL-2R signaling in Tregs from patients with autoimmunity to restore regulation to endogenous Tregs will be the subject of his presentation. He is a co-founder of IL-2Rx/Ativo.
A New Paradigm in Immunotherapy; Restoration of Endogenous Treg Function 3:00 pm
It is defective Treg function, not the number of Tregs that allows autoimmune disease. Our proprietary IL-2 protein drug conjugate (PDC) targets Tregs to enhance/restore function. Using the PDC, we successfully treated mouse models of SLE, MS, T1D and asthmaRead more
day: Day Two